<DOC>
	<DOC>NCT00786240</DOC>
	<brief_summary>The objective of this study is to demonstrate bioequivalence of 4 mg tablet of formulation D and formulation E(1).</brief_summary>
	<brief_title>Phase1, Single Dose, Crossover Study to Determine Bioequivalence</brief_title>
	<detailed_description />
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Healthy male or female Chinese or Japanese subjects Evidence or history of clinically significant findings at screening</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Therapeutic Equivalency</keyword>
</DOC>